Particle.news

Download on the App Store

Amgen Commits Over $600 Million to New R&D Center at Thousand Oaks Headquarters

The project signals a broader U.S. drive to strengthen domestic drug research through tax incentives alongside new FDA initiatives.

Overview

  • Construction is slated to begin in the third quarter of 2025 at the Thousand Oaks campus on a state-of-the-art science and innovation facility.
  • The center is an R&D hub, not a manufacturing plant, designed to bring together scientists, engineers and researchers with advanced automation and digital tools.
  • The project will replace the unused Building 14, with the new facility designated as Building 50 on Amgen’s headquarters campus.
  • Amgen says the build will create hundreds of U.S. jobs, demolition will be performed by union labor, and a general contractor has not yet been selected.
  • The investment extends nearly $5 billion in U.S. capital spending since 2017 and follows a $900 million Ohio expansion and a $1 billion Holly Springs, N.C., plant, reflecting political and regulatory tailwinds for domestic capacity.